Efficacy of Glutathione for Patients With Cystic Fibrosis: A Meta-analysis of Randomized-Controlled Studies.
Efficacy of Glutathione for Patients With Cystic Fibrosis: A Meta-analysis of Randomized-Controlled Studies. Am J Rhinol Allergy. 2019 Sep 24;:1945892419878315 Authors: Zhao J, Huang W, Zhang S, Xu J, Xue W, He B, Zhang Y PMID: 31550169 [PubMed - as supplied by publisher]
CONCLUSION: Our results did not show that S. aureus found in nasal mucosa membrane is significantly different in patients with or without NP. However, association of the presence of S. aureus in patients with nasal polyposis with asthma, allergy and inflammation has been shown. PMID: 31785225 [PubMed - as supplied by publisher]
Usually B is perceived as a purely neutrophilic disease. However, eosinophilic type of inflammation is observed in pts with B in clinical practice. The aim of the study was to determine the correlation between blood eosinophils level and sensitization to Aspergillus fumigatus (AF).Methods: The study included cohort of pts with confirmed by HRCT B. Peripheral blood eosinophils were counted in stable phase. Total serum IgE was evaluated by using conventional electrochemiluminescence immunoassay (ECLIA) and specific IgE to AF was measured by immunoCAP technology. The methods of descriptive statistics and non-parametric statis...
In this study, OVA-sensitized/challenged mice were treated with AZM after inoculation with RSV. We found that AZM treatment not only suppressed AHR, but also reduced all key markers of exacerbation. Furthermore, TNFa-produced by alveolar macrophages was reduced with AZM treatment. Recombinant TNFa administration could reverse exacerbation in the presence of AZM. Our findings highlight the mechanism of AZM suppressed AHR and airway inflammation in RSV-induced asthma exacerbation through targeting the innate immune response linked to alveolar macrophages and TNFa production.
Conclusions. The applied diagnostic criteria had no significant effect on the reported rate of ABPA prevalence. PMID: 31702121 [PubMed - as supplied by publisher]
The major cause of lung damage in cystic fibrosis (CF) is infection with bacterial pathogens, the most prevalent of which is Pseudomonas aeruginosa, chronically infecting ~60% patients by adolescence/adulthood (www.cysticfibrosis.org.uk/news/registry-report-2017). P. aeruginosa may be successfully eradicated, but frequently recurs and establishes biofilms resistant to antibiotics/host defences . Chronic P. aeruginosa is closely linked with pulmonary exacerbation frequency, faster lung function decline and earlier mortality . The huge antibiotic burden imposed upon patients and the resulting bacterial resist...
Inhaled and oral glutathione may benefit lung function in patients with cystic fibrosis (CF), although vitamin and mineral antioxidant supplementation does not appear to have a positive treatment effect, an updated Cochrane Review reveals.Reuters Health Information
We present a 23-year-old male with a history of cystic fibrosis (CF) with associated renal disease, bronchiectasis, pneumothorax, and distal intestinal obstruction syndrome admitted for CF exacerbation. Sputum culture was positive for methicillin resistant Staphylococcus aureus (MRSA). Chest imaging revealed extensive opacities in the left lung. His FEV1 during admission was 52% (baseline 70%). Allergy was consulted as inhaled vancomycin therapy was preferred, but the patient had previous vancomycin-induced reactions.
High antibiotic utilization is an essential element of life-saving care for cystic fibrosis (CF) patients. However, adverse drug reactions (ADRs) to antibiotics occur more commonly and discrete types of ADRs may differ in CF patients compared to the general population. Characterization of documented ADRs among CF patients is needed in order understand how antibiotic utilization can be improved for CF patients.
Allergic bronchopulmonary aspergillosis (ABPA) affects up to 15% of patients with cystic fibrosis (CF), representing a significant clinical challenge. It is especially a concern in the pediatric population given adverse effects of steroids in this population. Here we report on the use of omalizumab in the treatment of steroid-resistant ABPA in a pediatric patient with CF.
Reactions were much more common in patients with cystic fibrosis and those with previously identified environmental or drug allergies.Medscape Medical News